Search

Your search keyword '"Stockmann, H.B.A.C."' showing total 32 results
Start Over Author "Stockmann, H.B.A.C."
32 results on '"Stockmann, H.B.A.C."'

2. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Author

Kitzen, J.J.E.M., Strobbe, L.J.A., Kouwenhoven, E.A., van Dalen, T., van Overbeeke, A.J., Nuytinck, J.K.S., Arntz, I.E., Blaisse, R.J.B., Stockmann, H.B.A.C., Nijhuis, P.H.A., Veldhuis, G.J., Mastboom, W.J.B., van Riel, J.M.G.H., van Dam, J.H., den Boer, M.O., Agterof, M.J., de Roos, M.A.J., Roumen, R.M.H., van der Hoeven, J.J.M., Beeker, A., Koelemij, R., van Bochove, A., Madretsma, G.S., Siemerink, E.J.M., Guicherit, O.R., Vos, A.H., Nieuwenhuijzen, G.A.P., Kehrer, D.F.S., Valster, F.A.A., Tanis, B.C., van Voorthuizen, T., van der Velden, A.M.T., Hellingman, R.A., Vree, R., van Rossum-Schornagel, Q., Meerum Terwogt, J.M., van Leeuwen-Breuk, W.G., Haasjes, J.G., Davidis-van Schoonhoven, M.A., Vriens, E.J.C., Jagers, M., Muller, E.W., Schiphorst, P.P.J.B.M., van Groeningen, C.J., van Dijk, M.A., Janssens- van Vliet, E., Schepers, E.E.M., Merkus, J.W.S., van Diemen, N.G.J., van Doorn, R.C., Bosscha, K., den Toom, R., van der Velden, P.C., van Rossum, C.T.A.M., Oosterkamp, H.M., van Hillegersberg, R., Jas, B., Weernink, E.E.M., Ketel, J.M.A., Jansen, J.J., Maring, J.K., Govaert, M.J.P.M., Kamm, Y.J.L., Vleugel, M.M., Hovenga, S., de Boer, J., Potthoff, H., Sommeijer, D.W., van Dulken, E.J., Tjan-Heijnen, Vivianne C G, van Hellemond, Irene E G, Peer, Petronella G M, Swinkels, Astrid C P, Smorenburg, Carolien H, van der Sangen, Maurice J C, Kroep, Judith R, De Graaf, Hiltje, Honkoop, Aafke H, Erdkamp, Frans L G, van den Berkmortel, Franchette W P J, de Boer, Maaike, de Roos, Wilfred K, Linn, Sabine C, Imholz, Alexander L T, and Seynaeve, Caroline M

Published
2017
Full Text
View/download PDF

5. Objective Assessment of Fitness to Perform (FTOP) After Surgical Night Shifts in the Netherlands

Author

Tummers, F.H.M.P., Huizinga, C.R.H., Stockmann, H.B.A.C., Hamming, J.F., Cohen, A.F., Bogt, K.E.A. van der, Steenhoven, T.J. van der, Kam, M. de, Pampus, M.G. van, Oordt, C. .J. van, Legemate, D.A., Toorenvliet, B.R., Wever, J.J., Lijkwan, M.A., and FTOP Collaborators

Subjects
Male, Self-assessment, Self-Assessment, night shift, medicine.medical_specialty, Consultants, work hour directive, MEDLINE, night call, Objective assessment, Cohort Studies, 03 medical and health sciences, fit to perform, 0302 clinical medicine, After-Hours Care, Work Schedule Tolerance, Task Performance and Analysis, patient safety, Humans, Medicine, Attention, Prospective Studies, sleep-deprived, Prospective cohort study, work hours, alertness, Netherlands, Surgeons, business.industry, Internship and Residency, Reproducibility of Results, organization of care, Alertness, Physical Fitness, General Surgery, 030220 oncology & carcinogenesis, Physical therapy, Female, fatigue, 030211 gastroenterology & hepatology, Surgery, Observational study, Clinical Competence, business, Cohort study
Abstract

Background: Surgical skills and decision making are influenced by alertness, reaction time, eye-hand coordination, and concentration. Night shift might impair these functions but it is unclear to what extent. The aim of this study was to investigate whether a night shift routinely impairs the surgeon's fitness to perform and whether this reaches a critical limit as compared to relevant frames of reference.Methods: Consultants (n = 59) and residents (n = 103) conducted fitness to perform measurements at precall, postcall, and noncall moments. This validated self-test consists of an adaptive tracker that is able to objectively measure alertness, reaction time, concentration, and eye-hand coordination, and multiple visual analog scales to subjectively score alertness. Results are compared to sociolegal (ethanol) and professional (operative skills) frames of reference that refer to a decrease under the influence of 0.06% ethanol.Results: Residents spent 1.7 call hours asleep on average as compared to 5.4 for consultants. Subjective alertness decreased in residents after night shifts (-13, P < 0.001) but not in consultants (-1.2, P = NS). The overnight difference in tracker score was -1.17 (P < 0.001) for residents and 0.46 (P = NS) for surgeons. Postcall subjective alertness only correlated to objective alertness in consultants. For residents, hours slept on-call correlated to objective alertness. For consultants, subsequent night calls significantly correlated to objective alertness, with the third subsequent call related to performance below the reference.Conclusions: Consultants remain fit to perform after night call, but subsequent calls may compromise clinical activities. This study provides insight and awareness of individual performance with clear frames of reference.

Published
2019
Full Text
View/download PDF

6. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care

Author

Derksen, J.W.G. (Jeroen W. G.), Vink, G.R. (Geraldine R.), Elferink, M.A.G. (Marloes), Roodhart, J.M. (Jeanine), Verkooijen, H.M. (Helena M.), Grevenstein, H.M.U. (Helma) van, Siersema, P.D. (Peter), May, A.M. (Anne M.), Koopman, M. (Miriam), Beets, G.L. (Geerard), Belt, E.J.T. (Eric), Berbée, M. (Maaike), Beverdam, F.H. (Frederique H.), Blankenburgh, R. (Ruud), Coene, P-P. (Peter Paul), van Cruijsen, H. (Hester), Dekker, J.W.T. (Jan Willem), van Dodewaard-de Jong, J.M. (Joyce M.), Erdkamp, F.L.G. (Frans ), Groot, J.W.B. (Jan Willem) de, Haringhuizen, A.W. (Annebeth W.), Helgason, H.H. (Helgi H.), Hendriks, M.P. (Mathijs P.), Hingh, I.H.J.T. (Ignace) de, Hoekstra, R. (Ronald), IJzermans, J.N.M. (Jan), Jansen, J. (Jan), Kloppenberg, F.W.H. (Frank W. H.), Lent, A.U. (Anja) van, Los, M., Meijerink, M.R. (Martijn R.), Mekenkamp, L.J.M. (Leonie J. M.), Nieboer, P. (Peter), Peeters, K.C.M.J. (Koen C.M.J.), Peters, N.A.J.B. (Natascha A. J. B.), Polee, M.B. (Marco), Pruijt, J.F.M., Punt, C.J.A. (Cornelis), van Ufford-Mannesse, P.Q. (Patricia Quarles), Rietbroek, R.C. (Ron), Schiphorst, A.H.W. (Anandi H. W.), van der Velden, A.S. (Arjan Schouten), Schrauwen, R.W.M. (Ruud W. M.), Sie, M.P.S. (Mark P. S.), Simkens, L.H.J. (L. H J), Sommeijer, D.W. (Dirkje W.), Sonneveld, D.J.A., Spierings, L.E.A. (Leontine E. A.), Stockmann, H.B.A.C. (Hein), Talsma, A.K. (Aaldert), Terheggen, F. (Frederiek), Tije, A.J. (Albert Jan) ten, Tjin-A-Ton, M.L.R. (Manuel L. R.), Valkenburg-van Iersel, L.B.J. (Liselot B. J.), Veenstra, R.P., Velden, A.M.T. van der, Vermaas, M. (Maarten), Vles, W., Vogelaar, J.F.J. (Jeroen F. J.), van Voorthuizen, T. (Theo), Vos, A.I. (Aad) de, Wegdam, J.A. (J.), Wilt, J.H.W. (Johannes) de, Zimmerman, D.D.E. (David), Derksen, J.W.G. (Jeroen W. G.), Vink, G.R. (Geraldine R.), Elferink, M.A.G. (Marloes), Roodhart, J.M. (Jeanine), Verkooijen, H.M. (Helena M.), Grevenstein, H.M.U. (Helma) van, Siersema, P.D. (Peter), May, A.M. (Anne M.), Koopman, M. (Miriam), Beets, G.L. (Geerard), Belt, E.J.T. (Eric), Berbée, M. (Maaike), Beverdam, F.H. (Frederique H.), Blankenburgh, R. (Ruud), Coene, P-P. (Peter Paul), van Cruijsen, H. (Hester), Dekker, J.W.T. (Jan Willem), van Dodewaard-de Jong, J.M. (Joyce M.), Erdkamp, F.L.G. (Frans ), Groot, J.W.B. (Jan Willem) de, Haringhuizen, A.W. (Annebeth W.), Helgason, H.H. (Helgi H.), Hendriks, M.P. (Mathijs P.), Hingh, I.H.J.T. (Ignace) de, Hoekstra, R. (Ronald), IJzermans, J.N.M. (Jan), Jansen, J. (Jan), Kloppenberg, F.W.H. (Frank W. H.), Lent, A.U. (Anja) van, Los, M., Meijerink, M.R. (Martijn R.), Mekenkamp, L.J.M. (Leonie J. M.), Nieboer, P. (Peter), Peeters, K.C.M.J. (Koen C.M.J.), Peters, N.A.J.B. (Natascha A. J. B.), Polee, M.B. (Marco), Pruijt, J.F.M., Punt, C.J.A. (Cornelis), van Ufford-Mannesse, P.Q. (Patricia Quarles), Rietbroek, R.C. (Ron), Schiphorst, A.H.W. (Anandi H. W.), van der Velden, A.S. (Arjan Schouten), Schrauwen, R.W.M. (Ruud W. M.), Sie, M.P.S. (Mark P. S.), Simkens, L.H.J. (L. H J), Sommeijer, D.W. (Dirkje W.), Sonneveld, D.J.A., Spierings, L.E.A. (Leontine E. A.), Stockmann, H.B.A.C. (Hein), Talsma, A.K. (Aaldert), Terheggen, F. (Frederiek), Tije, A.J. (Albert Jan) ten, Tjin-A-Ton, M.L.R. (Manuel L. R.), Valkenburg-van Iersel, L.B.J. (Liselot B. J.), Veenstra, R.P., Velden, A.M.T. van der, Vermaas, M. (Maarten), Vles, W., Vogelaar, J.F.J. (Jeroen F. J.), van Voorthuizen, T. (Theo), Vos, A.I. (Aad) de, Wegdam, J.A. (J.), Wilt, J.H.W. (Johannes) de, and Zimmerman, D.D.E. (David)

Abstract

Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the “real-world”. Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013–2016 and 2017–Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64–0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017–Aug’19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC’s representativeness and its contribution to a learning healthcare system.

Published
2021
Full Text
View/download PDF

7. Nationwide comprehensive gastro-intestinal cancer cohorts

Author

Braak, R.R.J.C. van den, Rijssen, L.B. van, Kleef, J.J. van, Vink, G.R., Berbee, M., Henegouwen, M.I.V., Bloemendal, H.J., Bruno, M.J., Burgmans, M.C., Busch, O.R.C., Coene, P.P.L.O., Coupe, V.M.H., Dekker, J.W.T., Eijck, C.H.J. van, Elferink, M.A.G., Erdkamp, F.L.G., Grevenstein, W.M.U. van, Groot, J.W.B. de, Grieken, N.C.T. van, Hingh, I.H.J.T. de, Hulshof, M.C.C.M., Ijzermans, J.N.M., Kwakkenbos, L., Lemmens, V.E.P.P., M. los, Meijer, G.A., Molenaar, I.Q., Nieuwenhuijzen, G.A.P., Noo, M.E. de, Poll-Franse, L.V. van de, Punt, C.J.A., Rietbroek, R.C., Roeloffzen, W.W.H., Rozema, T., Ruurda, J.P., Sandick, J.W. van, Schiphorst, A.H.W., Schipper, H., Siersema, P.D., Slingerland, M., Sommeijer, D.W., Spaander, M.C.W., Sprangers, M.A.G., Stockmann, H.B.A.C., Strijker, M., Tienhoven, G. van, Timmermans, L.M., Tjin-a-Ton, M.L.R., Velden, A.M.T. van der, Verhaar, M.J., Verkooijen, H.M., Vles, W.J., Vos-Geelen, J.M.P.G.M. de, Wilmink, J.W., Zimmerman, D.D.E., Oijen, M.G.H. van, Koopman, M., Besselink, M.G.H., Laarhoven, H.W.M. van, Dutch Pancreatic Canc Grp, Dutch Upper GI Canc Grp, PLCRC Working Grp, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Promovendi ODB, MUMC+: MA Radiotherapie OC (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), CCA - Cancer Treatment and quality of life, APH - Methodology, Epidemiology and Data Science, AGEM - Re-generation and cancer of the digestive system, Pathology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Surgery, Graduate School, Radiotherapy, Oncology, APH - Aging & Later Life, APH - Mental Health, Medical Psychology, APH - Quality of Care, Gastroenterology & Hepatology, Public Health, Erasmus MC other, and Medical and Clinical Psychology

Subjects
0301 basic medicine, medicine.medical_specialty, INFRASTRUCTURE, law.invention, COLORECTAL-CANCER, Cohort Studies, Experimental Psychopathology and Treatment, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Randomized controlled trial, SDG 3 - Good Health and Well-being, DESIGN, law, Informed consent, MOLECULAR SUBTYPES, medicine, Humans, QUALITY, Radiology, Nuclear Medicine and imaging, Registries, Biological Specimen Banks, Gastrointestinal Neoplasms, Randomized Controlled Trials as Topic, ESOPHAGEAL, INFORMED-CONSENT, business.industry, Clinical study design, Cancer, Hematology, General Medicine, medicine.disease, Surgery, Cancer registry, Clinical trial, Observational Studies as Topic, 030104 developmental biology, Oncology, Research Design, 030220 oncology & carcinogenesis, Cohort, Emergency medicine, business, CLINICAL-TRIALS, Cohort study
Abstract

Contains fulltext : 190038.pdf (Publisher’s version ) (Open Access) Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting. 8 p.

Published
2018
Full Text
View/download PDF

8. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative

Author

Coebergh van den Braak, R.R.J. (Robert), van Rijssen, L.B. (Lennart B.), van Kleef, J.J. (J. J.), Vink, G.R. (G. R.), Berbee, M. (M.), van Berge Henegouwen, M.I., Bloemendal, H.J. (Haiko), Bruno, M.J. (Marco), Burgmans, M.C. (M. C.), Busch, O.R.C. (Olivier), Coene, P-P. (Peter Paul), Coupé, V.M.H. (Veerle), Dekker, J.W.T. (Jan Willem), Eijck, C.H.J. (Casper) van, Elferink, M.A.G. (Marloes), Erdkamp, F.L.G. (Frans ), Grevenstein, H.M.U. (Helma) van, Groot, J.W.B. (Jan Willem) de, Grieken, N.C.T. (Nicole), Hingh, I.H.J.T. (Ignace) de, Hulshof, M.C.C.M. (Maarten), IJzermans, J.N.M. (Jan), Kwakkenbos, L. (L.), Lemmens, V.E.P.P. (Valery), Los, M., Meijer, C.J.L.M. (Chris), Molenaar, I.Q. (I. Quintus), Nieuwenhuijzen, G.A.P. (Gerard), de Noo, M.E. (M. E.), Poll-Franse, L.V. (Lonneke) van de, Punt, C.J.A. (Cornelis), Rietbroek, R.C. (Ron), Roeloffzen, W.W.H. (W. W.H.), Rozema, T. (Tom), Ruurda, J.P. (Jelle), Sandick, J.W. (J.) van, Schiphorst, A.H.W. (A. H.W.), Schipper, H. (H.), Siersema, P.D. (Peter), Slingerland, M. (Marije), Sommeijer, D.W. (D. W.), Spaander, M.C.W. (Manon), Sprangers, M.A.G. (Mirjam), Stockmann, H.B.A.C. (Hein), Strijker, M. (M.), Tienhoven, G. (Geertjan) van, Timmermans, L.M. (L. M.), Tjin-a-Ton, M.L.R. (M. L.R.), Velden, A.M.T. van der, Verhaar, M.J. (M. J.), Verkooijen, H.M. (Helena M.), Vles, W., de Vos-Geelen, J. (Judith), Wilmink, J.W. (Johanna), Zimmerman, D.D.E. (David), Oijen, M.G.H. (Martijn) van, Koopman, M. (Miriam), Besselink, M.G. (Marc), Laarhoven, H.W.M. (Hanneke) van, Coebergh van den Braak, R.R.J. (Robert), van Rijssen, L.B. (Lennart B.), van Kleef, J.J. (J. J.), Vink, G.R. (G. R.), Berbee, M. (M.), van Berge Henegouwen, M.I., Bloemendal, H.J. (Haiko), Bruno, M.J. (Marco), Burgmans, M.C. (M. C.), Busch, O.R.C. (Olivier), Coene, P-P. (Peter Paul), Coupé, V.M.H. (Veerle), Dekker, J.W.T. (Jan Willem), Eijck, C.H.J. (Casper) van, Elferink, M.A.G. (Marloes), Erdkamp, F.L.G. (Frans ), Grevenstein, H.M.U. (Helma) van, Groot, J.W.B. (Jan Willem) de, Grieken, N.C.T. (Nicole), Hingh, I.H.J.T. (Ignace) de, Hulshof, M.C.C.M. (Maarten), IJzermans, J.N.M. (Jan), Kwakkenbos, L. (L.), Lemmens, V.E.P.P. (Valery), Los, M., Meijer, C.J.L.M. (Chris), Molenaar, I.Q. (I. Quintus), Nieuwenhuijzen, G.A.P. (Gerard), de Noo, M.E. (M. E.), Poll-Franse, L.V. (Lonneke) van de, Punt, C.J.A. (Cornelis), Rietbroek, R.C. (Ron), Roeloffzen, W.W.H. (W. W.H.), Rozema, T. (Tom), Ruurda, J.P. (Jelle), Sandick, J.W. (J.) van, Schiphorst, A.H.W. (A. H.W.), Schipper, H. (H.), Siersema, P.D. (Peter), Slingerland, M. (Marije), Sommeijer, D.W. (D. W.), Spaander, M.C.W. (Manon), Sprangers, M.A.G. (Mirjam), Stockmann, H.B.A.C. (Hein), Strijker, M. (M.), Tienhoven, G. (Geertjan) van, Timmermans, L.M. (L. M.), Tjin-a-Ton, M.L.R. (M. L.R.), Velden, A.M.T. van der, Verhaar, M.J. (M. J.), Verkooijen, H.M. (Helena M.), Vles, W., de Vos-Geelen, J. (Judith), Wilmink, J.W. (Johanna), Zimmerman, D.D.E. (David), Oijen, M.G.H. (Martijn) van, Koopman, M. (Miriam), Besselink, M.G. (Marc), and Laarhoven, H.W.M. (Hanneke) van

Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients. Material and methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future. Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing. Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With t

Published
2018
Full Text
View/download PDF

9. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Author

Tjan-Heijnen, Vivianne C G, primary, van Hellemond, Irene E G, additional, Peer, Petronella G M, additional, Swinkels, Astrid C P, additional, Smorenburg, Carolien H, additional, van der Sangen, Maurice J C, additional, Kroep, Judith R, additional, De Graaf, Hiltje, additional, Honkoop, Aafke H, additional, Erdkamp, Frans L G, additional, van den Berkmortel, Franchette W P J, additional, de Boer, Maaike, additional, de Roos, Wilfred K, additional, Linn, Sabine C, additional, Imholz, Alexander L T, additional, Seynaeve, Caroline M, additional, Kitzen, J.J.E.M., additional, Strobbe, L.J.A., additional, Kouwenhoven, E.A., additional, van Dalen, T., additional, van Overbeeke, A.J., additional, Nuytinck, J.K.S., additional, Arntz, I.E., additional, Blaisse, R.J.B., additional, Stockmann, H.B.A.C., additional, Nijhuis, P.H.A., additional, Veldhuis, G.J., additional, Mastboom, W.J.B., additional, van Riel, J.M.G.H., additional, van Dam, J.H., additional, den Boer, M.O., additional, Agterof, M.J., additional, de Roos, M.A.J., additional, Roumen, R.M.H., additional, van der Hoeven, J.J.M., additional, Beeker, A., additional, Koelemij, R., additional, van Bochove, A., additional, Madretsma, G.S., additional, Siemerink, E.J.M., additional, Guicherit, O.R., additional, Vos, A.H., additional, Nieuwenhuijzen, G.A.P., additional, Kehrer, D.F.S., additional, Valster, F.A.A., additional, Tanis, B.C., additional, van Voorthuizen, T., additional, van der Velden, A.M.T., additional, Hellingman, R.A., additional, Vree, R., additional, van Rossum-Schornagel, Q., additional, Meerum Terwogt, J.M., additional, van Leeuwen-Breuk, W.G., additional, Haasjes, J.G., additional, Davidis-van Schoonhoven, M.A., additional, Vriens, E.J.C., additional, Jagers, M., additional, Muller, E.W., additional, Schiphorst, P.P.J.B.M., additional, van Groeningen, C.J., additional, van Dijk, M.A., additional, Janssens- van Vliet, E., additional, Schepers, E.E.M., additional, Merkus, J.W.S., additional, van Diemen, N.G.J., additional, van Doorn, R.C., additional, Bosscha, K., additional, den Toom, R., additional, van der Velden, P.C., additional, van Rossum, C.T.A.M., additional, Oosterkamp, H.M., additional, van Hillegersberg, R., additional, Jas, B., additional, Weernink, E.E.M., additional, Ketel, J.M.A., additional, Jansen, J.J., additional, Maring, J.K., additional, Govaert, M.J.P.M., additional, Kamm, Y.J.L., additional, Vleugel, M.M., additional, Hovenga, S., additional, de Boer, J., additional, Potthoff, H., additional, Sommeijer, D.W., additional, and van Dulken, E.J., additional

Published
2017
Full Text
View/download PDF

11. Expression of Apoptosis Regulating Proteins Identifies Stage II and III Colon Cancer Patients With High Risk of Recurrence

Author

Belt, E.J.T., Stockmann, H.B.A.C., van Diemen, P.M., Bril, H., Tijssen, M., van Essen, H.F., Heymans, M.W., Belien, J.A.M., Carvalho, B., Cillessen, S.A.G.M., Meijer, G.A., Pathology, Epidemiology and Data Science, CCA - Disease profiling, and Methodology and Applied Biostatistics

Subjects
SDG 3 - Good Health and Well-being
Abstract

Background and Objectives Deregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. Methods From tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl-2, Bcl-X, BAX, XIAP, Fas, FasL and c-FLIP was evaluated and PCR-based microsatellite instability analysis was performed. Results High FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl-X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl-XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl-2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl-2, Fas and FasL expression was significantly associated with DFS. Conclusions Stage II patients with low Bcl-X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl-2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255-265. © 2013 Wiley Periodicals, Inc.

Published
2014
Full Text
View/download PDF

12. Cost-effectiveness of selective decontamination of the digestive tract to decrease infectious complications in colorectal cancer surgery: An analysis of the SELECT trial.

Author

Reuvers, J.R.D., Gaikhorst, E., Ben, Â. Jornada, Scholten, J., van Egmond, M., Bosmans, J.E., Stockmann, H.B.A.C., Kazemier, G., Tuynman, J.B., Abis, G.S.A., and Oosterling, S.J.

Subjects
ALIMENTARY canal, ANTIBIOTIC prophylaxis, PROCTOLOGY, COLORECTAL cancer, ONCOLOGIC surgery, ELECTIVE surgery, CANCER complications
Abstract

Selective decontamination of the digestive tract (SDD) is effective in reducing infectious complications in elective colorectal cancer (CRC) surgery. However, it is unclear whether SDD is cost-effective compared to standard antibiotic prophylaxis. Economic evaluation alongside multicenter randomized controlled trial, the SELECT-trial, from a healthcare perspective. Patients included underwent elective surgery for non-metastatic CRC. The intervention group received oral non-absorbable colistin, tobramycin and amphotericin B (SDD) next to standard antibiotic prophylaxis. Both groups received a single shot intravenous cefazolin and metronidazole preoperatively as standard prophylaxis. Occurrence of postoperative infectious complication in the first 30 postoperative days was extracted from medical records, Quality-Adjusted Life-Years (QALYs) based on the ED-5D-3L, and healthcare costs collected from the hospital's financial administration. Of the 455 patients, 228 were randomly assigned to intervention group and 227 patients to the control group. SDD significantly reduced the number of infectious complications compared to control (difference = −0.13, 95 % CI -0.05 to −0.20). No difference was found for QALYs (difference = 0.002, 95 % CI -0.002 to 0.005). Healthcare costs were statistically significantly lower in the intervention group (difference = −€1258, 95 % CI -2751 to −166). The ICER was −9872 €/infectious complication prevented and −820,380 €/QALY gained. For all willingness-to-pay thresholds, the probability that prophylactic SDD was cost-effective compared to standard prophylactic practice alone was 1.0. The addition of SDD to the standard preoperative intravenous antibiotic prophylaxis is cost-effective compared to standard prophylactic practice from a healthcare perspective and should be considered as the standard of care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Prognostic value ofBRAFandKRASmutation status in stage II and III microsatellite instable colon cancers

Author

de Cuba, E.M.V., primary, Snaebjornsson, P., additional, Heideman, D.A.M., additional, van Grieken, N.C.T., additional, Bosch, L.J.W., additional, Fijneman, R.J.A., additional, Belt, E., additional, Bril, H., additional, Stockmann, H.B.A.C., additional, Hooijberg, E., additional, Punt, C.J.A., additional, Koopman, M., additional, Nagtegaal, I.D., additional, Coupé, V.H.M., additional, Carvalho, B., additional, and Meijer, G.A., additional

Published
2015
Full Text
View/download PDF

16. The Ladies trial: laparoscopic peritoneal lavage or resection for purulent peritonitis and Hartmann's procedure or resection with primary anastomosis for purulent or faecal peritonitis in perforated diverticulitis (NTR2037)

Author

Swank, H.A., Vermeulen, J., Lange, J.F., Mulder, I.M., Hoeven, J.A.B. van der, Stassen, L.P.S., Crolla, R.M.P.H., Sosef, M.N., Nienhuijs, S.W., Bosker, R.J.I., Boom, M.J., Kruyt, P.M., Swank, D.J., Steup, W.H., Graaf, E.J.R. de, Weidema, W.F., Pierik, R.E.G.J.M., Prins, H.A., Stockmann, H.B.A.C., Tollenaar, R.A.E.M., Wagensveld, B.A. van, Coene, P.P.L.O., Slooter, G.D., Consten, E.C.J., Duijn, E.B. van, Gerhards, M.F., Hoofwijk, A.G.M., Karsten, T.M., Neijenhuis, P.A., Blanken-Peeters, C.F.J.M., Cense, H.A., Mannaerts, G.H.H., Bruin, S.C., Eijsbouts, Q.A.J., Wiezer, M.J., Hazebroek, E.J., Geloven, A.A.W. van, Maring, J.K., D'Hoore, A.J.L., Kartheuser, A., Remue, C., Grevenstein, H.M.U. van, Konsten, J.L.M., Peet, D.L. van der, Govaert, M.J.P.M., Engel, A.F., Reitsma, J.B., Bemelman, W.A., Dutch Diverticular Dis 3D, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, APH - Amsterdam Public Health, Epidemiology and Data Science, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, Pediatrics, Radiology & Nuclear Medicine, Nutrition and Movement Sciences, and RS: NUTRIM - R2 - Gut-liver homeostasis

Subjects
Adult, medicine.medical_specialty, Adolescent, medicine.medical_treatment, lcsh:Surgery, Peritonitis, Anastomosis, Diverticulitis - complications, Study Protocol, Sigmoidectomy, Colostomy, medicine, Clinical endpoint, Humans, Peritoneal Lavage, Laparoscopy, Colectomy, Diverticulitis, Aged, Aged, 80 and over, medicine.diagnostic_test, business.industry, General surgery, Peritoneal Lavage - methods, Anastomosis, Surgical, General Medicine, lcsh:RD1-811, Middle Aged, medicine.disease, Surgery, Treatment Outcome, Intestinal Perforation, Peritonitis - etiology, surgery, Female, business, Intestinal Perforation - etiology, surgery
Abstract

Background Recently, excellent results are reported on laparoscopic lavage in patients with purulent perforated diverticulitis as an alternative for sigmoidectomy and ostomy. The objective of this study is to determine whether LaparOscopic LAvage and drainage is a safe and effective treatment for patients with purulent peritonitis (LOLA-arm) and to determine the optimal resectional strategy in patients with a purulent or faecal peritonitis (DIVA-arm: perforated DIVerticulitis: sigmoidresection with or without Anastomosis). Methods/Design In this multicentre randomised trial all patients with perforated diverticulitis are included. Upon laparoscopy, patients with purulent peritonitis are treated with laparoscopic lavage and drainage, Hartmann's procedure or sigmoidectomy with primary anastomosis in a ratio of 2:1:1 (LOLA-arm). Patients with faecal peritonitis will be randomised 1:1 between Hartmann's procedure and resection with primary anastomosis (DIVA-arm). The primary combined endpoint of the LOLA-arm is major morbidity and mortality. A sample size of 132:66:66 patients will be able to detect a difference in the primary endpoint from 25% in resectional groups compared to 10% in the laparoscopic lavage group (two sided alpha = 5%, power = 90%). Endpoint of the DIVA-arm is stoma free survival one year after initial surgery. In this arm 212 patients are needed to significantly demonstrate a difference of 30% (log rank test two sided alpha = 5% and power = 90%) in favour of the patients with resection with primary anastomosis. Secondary endpoints for both arms are the number of days alive and outside the hospital, health related quality of life, health care utilisation and associated costs. Discussion The Ladies trial is a nationwide multicentre randomised trial on perforated diverticulitis that will provide evidence on the merits of laparoscopic lavage and drainage for purulent generalised peritonitis and on the optimal resectional strategy for both purulent and faecal generalised peritonitis. Trial registration Nederlands Trial Register NTR2037

Published
2010
Full Text
View/download PDF

18. A multicenter randomized controlled trial evaluating the effect of small stitches on the incidence of incisional hernia in midline incisions

Author

Harlaar, J.J. (Joris Jan), Deerenberg, E.B. (Eva), Ramshorst, G.H. (Gabrielle) van, Lont, H.E. (Harold), Borst, E.C.M.H. (Ed) van der, Schouten, W.R. (Willem), Heisterkamp, J. (Joos), Doorn, H.C. (Lena) van, Cense, H.A. (Huib), Berends, F.J. (Frits), Stockmann, H.B.A.C. (Hein), Vrijland, W.W. (Wietske), Consten, E.C. (Esther), Ottow, R.T. (Reyer), Go, P.M.N.Y.H. (Peter), Hermans, J.J. (John), Steyerberg, E.W. (Ewout), Lange, J.F. (Johan), Harlaar, J.J. (Joris Jan), Deerenberg, E.B. (Eva), Ramshorst, G.H. (Gabrielle) van, Lont, H.E. (Harold), Borst, E.C.M.H. (Ed) van der, Schouten, W.R. (Willem), Heisterkamp, J. (Joos), Doorn, H.C. (Lena) van, Cense, H.A. (Huib), Berends, F.J. (Frits), Stockmann, H.B.A.C. (Hein), Vrijland, W.W. (Wietske), Consten, E.C. (Esther), Ottow, R.T. (Reyer), Go, P.M.N.Y.H. (Peter), Hermans, J.J. (John), Steyerberg, E.W. (Ewout), and Lange, J.F. (Johan)

Abstract

Background: The median laparotomy is frequently used by abdominal surgeons to gain rapid and wide access to the abdominal cavity with minimal damage to nerves, vascular structures and muscles of the abdominal wall. However, incisional hernia remains the most common complication after median laparotomy, with reported incidences varying between 2-20%. Recent clinical and experimental data showed a continuous suture technique with many small tissue bites in the aponeurosis only, is possibly more effective in the prevention of incisional hernia when compared to the common used large bite technique or mass closure. Methods/Design. The STITCH trial is a double-blinded multicenter randomized controlled trial designed to compare a standardized large bite technique with a standardized small bites technique. The main objective is to compare both suture techniques for incidence of incisional hernia after one year. Secondary outcomes will include postoperative complications, direct costs, indirect costs and quality of life. A total of 576 patients will be randomized between a standardized small bites or large bites technique. At least 10 departments of general surgery and two departments of oncological gynaecology will participate in this trial. Both techniques have a standardized amount of stitches per cm wound length and suture length wound length ratio's are calculated in each patient. Follow up will be at 1 month for wound infection and 1 year for incisional hernia. Ultrasound examinations will be performed at both time points to measure the distance between the rectus muscles (at 3 points) and to objectify presence or absence of incisional hernia. Patients, investigators and radiologists will be blinded during follow up, although the surgeon can not be blinded during the surgical procedure. Conclusion: The STITCH trial will provide level 1b evidence to support the preference for either a continuous suture technique with many small tissue bites in the aponeurosis only or fo

Published
2011
Full Text
View/download PDF

19. The ladies trial: Laparoscopic peritoneal lavage or resection for purulent peritonitisA and Hartmann's procedure or resection with primary anastomosis for purulent or faecal peritonitisB in perforated diverticulitis (NTR2037)

Author

Swank, D.J. (Dingeman), Vermeulen, J. (Jefrey), Lange, J.F. (Johan), Mulder, I.M. (Irene), Hoeven, J.A.B. (Joost) van der, Stassen, L.P. (Laurents), Crolla, R.M.P.H. (Rogier), Sosef, M.N. (Meindert), Nienhuijs, S.W. (Simon), Bosker, R.J.I. (Robbert), Boom, M.J. (Maarten), Kruyt, Ph.M. (Philip), Steup, W.H. (Willem Hans), Graaf, E.J.R. (Eelco) de, Weidema, W.F. (Wibo), Pierik, R.E.G.J.M. (Robert), Prins, H.A. (Hubert), Stockmann, H.B.A.C., Tollenaar, R.A.E.M. (Rob), Wagensveld, B.A. (Bart) van, Coene, P-P. (Peter Paul), Slooter, G.D. (Gerrit), Consten, E.C. (Esther), Duijn, E.B. (Eino) van, Gerhards, M.F. (Michael), Hoofwijk, A.G.M. (Anton), Karsten, T.M. (Thomas), Neijenhuis, P.A. (Peter), Blanken-Peeters, C.F.J.M. (Charlotte), Cense, H.A. (Huib), Mannaerts, G.H.H. (Guido), Bruin, S.C. (Sjoerd), Eijsbouts, Q.A. (Quirijn), Wiezer, M.J. (Marinus), Hazebroek, E.J. (Eric Jasper), Geloven, A.A. (Anna) van, Maring, J.K. (John), D'Hoore, A. (André), Kartheuser, A. (Alex), Remue, C. (Christophe), Grevenstein, H.M.U. (Helma) van, Konsten, J.L.M. (Joop), Peet, D.L. (Donald) van der, Govaert, M.J.P.M. (Marc), Engel, A.F. (Alexander), Reitsma, J.B. (Johannes), Bemelman, W.A. (Willem), Swank, D.J. (Dingeman), Vermeulen, J. (Jefrey), Lange, J.F. (Johan), Mulder, I.M. (Irene), Hoeven, J.A.B. (Joost) van der, Stassen, L.P. (Laurents), Crolla, R.M.P.H. (Rogier), Sosef, M.N. (Meindert), Nienhuijs, S.W. (Simon), Bosker, R.J.I. (Robbert), Boom, M.J. (Maarten), Kruyt, Ph.M. (Philip), Steup, W.H. (Willem Hans), Graaf, E.J.R. (Eelco) de, Weidema, W.F. (Wibo), Pierik, R.E.G.J.M. (Robert), Prins, H.A. (Hubert), Stockmann, H.B.A.C., Tollenaar, R.A.E.M. (Rob), Wagensveld, B.A. (Bart) van, Coene, P-P. (Peter Paul), Slooter, G.D. (Gerrit), Consten, E.C. (Esther), Duijn, E.B. (Eino) van, Gerhards, M.F. (Michael), Hoofwijk, A.G.M. (Anton), Karsten, T.M. (Thomas), Neijenhuis, P.A. (Peter), Blanken-Peeters, C.F.J.M. (Charlotte), Cense, H.A. (Huib), Mannaerts, G.H.H. (Guido), Bruin, S.C. (Sjoerd), Eijsbouts, Q.A. (Quirijn), Wiezer, M.J. (Marinus), Hazebroek, E.J. (Eric Jasper), Geloven, A.A. (Anna) van, Maring, J.K. (John), D'Hoore, A. (André), Kartheuser, A. (Alex), Remue, C. (Christophe), Grevenstein, H.M.U. (Helma) van, Konsten, J.L.M. (Joop), Peet, D.L. (Donald) van der, Govaert, M.J.P.M. (Marc), Engel, A.F. (Alexander), Reitsma, J.B. (Johannes), and Bemelman, W.A. (Willem)

Abstract

Background: Recently, excellent results are reported on laparoscopic lavage in patients with purulent perforated diverticulitis as an alternative for sigmoidectomy and ostomy. The objective of this study is to determine whether LaparOscopic LAvage and drainage is a safe and effective treatment for patients with purulent peritonitis (LOLA-arm) and to determine the optimal resectional strategy in patients with a purulent or faecal peritonitis (DIVA-arm: perforated DIVerticulitis: sigmoidresection with or without Anastomosis). Methods/Design: In this multicentre randomised trial all patients with perforated diverticulitis are included. Upon laparoscopy, patients with purulent peritonitis are treated with laparoscopic lavage and drainage, Hartmann's procedure or sigmoidectomy with primary anastomosis in a ratio of 2:1:1 (LOLA-arm). Patients with faecal peritonitis will be randomised 1:1 between Hartmann's procedure and resection with primary anastomosis (DIVA-arm). The primary combined endpoint of the LOLA-arm is major morbidity and mortality. A sample size of 132:66:66 patients will be able to detect a difference in the primary endpoint from 25% in resectional groups compared to 10% in the laparoscopic lavage group (two sided alpha = 5%, power = 90%). Endpoint of the DIVA-arm is stoma free survival one year after initial surgery. In this arm 212 patients are needed to significantly demonstrate a difference of 30% (log rank test two sided alpha = 5% and power

Published
2010
Full Text
View/download PDF

20. A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial)

Author

Ünlü, C.̧., Korte, N. (Niels) de, Daniels, L. (Lidewine), Consten, E.C. (Esther), Cuesta, M.A. (Miguel), Gerhards, M.F. (Michael), Geloven, A.A. (Anna) van, Zaag, E.S. (Edwin) van der, Hoeven, J.A.B. (Joost) van der, Klicks, R. (Rutger), Cense, H.A. (Huib), Roumen, R.M. (Rudi), Eijsbouts, Q.A. (Quirijn), Lange, J.F. (Johan), Fockens, P. (Paul), Borgie, C.A. (Corianne) de, Bemelman, W.A. (Willem), Reitsma, J.B. (Johannes), Stockmann, H.B.A.C., Vrouenraets, B.C. (Bart), Boermeester, M.A. (Marja), Ünlü, C.̧., Korte, N. (Niels) de, Daniels, L. (Lidewine), Consten, E.C. (Esther), Cuesta, M.A. (Miguel), Gerhards, M.F. (Michael), Geloven, A.A. (Anna) van, Zaag, E.S. (Edwin) van der, Hoeven, J.A.B. (Joost) van der, Klicks, R. (Rutger), Cense, H.A. (Huib), Roumen, R.M. (Rudi), Eijsbouts, Q.A. (Quirijn), Lange, J.F. (Johan), Fockens, P. (Paul), Borgie, C.A. (Corianne) de, Bemelman, W.A. (Willem), Reitsma, J.B. (Johannes), Stockmann, H.B.A.C., Vrouenraets, B.C. (Bart), and Boermeester, M.A. (Marja)

Abstract

Background. Conservative treatment of uncomplicated or mild diverticulitis usually includes antibiotic therapy. It is, however, uncertain whether patients with acute diverticulitis indeed benefit from antibiotics. In most guidelines issued by professional organizations antibiotics are considered mandatory in the treatment of mild diverticulitis. This advice lacks evidence and is merely based on experts' opinion. Adverse effects of the use of antibiotics are well known, including allergic reactions, development of bacterial resistance to antibiotics and other side-effects. Methods. A randomized multicenter pragmatic clinical trial comparing

Published
2010
Full Text
View/download PDF

21. Direct trial. Diverticulitis recurrences or continuing symptoms: Operative versus conservative Treatment. A Multicenter randomised clinical trial

Author

Wall, B.J.M. (Bryan) van de, Draaisma, W.A. (Werner), Consten, E.C. (Esther), Graaf, Y. (Yolanda) van der, Otten, M.H. (Marten Henk), Wit, G.A. (Ardine) de, Stel, H.F. (Henk) van, Gerhards, M.F. (Michael), Wiezer, M.J. (Marinus), Cense, H.A. (Huib), Stockmann, H.B.A.C. (Hein), Leijtens, J.W.A. (Jeroen), Zimmerman, D.D.E. (David), Belgers, E.H.J. (Eric), Wagensveld, B.A. (Bart) van, Sonneveld, E.D.J.A. (Eric), Prins, H.A. (Hubert), Coene, P-P. (Peter Paul), Karsten, T.M. (Thomas), Klaase, J.M. (Joost), Statius Muller, M.G. (Markwin), Crolla, R.M.P.H. (Rogier), Broeders, I.A.M.J. (Ivo), Wall, B.J.M. (Bryan) van de, Draaisma, W.A. (Werner), Consten, E.C. (Esther), Graaf, Y. (Yolanda) van der, Otten, M.H. (Marten Henk), Wit, G.A. (Ardine) de, Stel, H.F. (Henk) van, Gerhards, M.F. (Michael), Wiezer, M.J. (Marinus), Cense, H.A. (Huib), Stockmann, H.B.A.C. (Hein), Leijtens, J.W.A. (Jeroen), Zimmerman, D.D.E. (David), Belgers, E.H.J. (Eric), Wagensveld, B.A. (Bart) van, Sonneveld, E.D.J.A. (Eric), Prins, H.A. (Hubert), Coene, P-P. (Peter Paul), Karsten, T.M. (Thomas), Klaase, J.M. (Joost), Statius Muller, M.G. (Markwin), Crolla, R.M.P.H. (Rogier), and Broeders, I.A.M.J. (Ivo)

Abstract

Background: Persisting abdominal complaints are common after an episode of diverticulitis treated conservatively. Furthermore, some patients develop frequent recurrences. These two groups of patients suffer greatly from their disease, as shown by impaired health related quality of life and increased costs due to multiple specialist consultations, pain medication and productivity losses. Both conservative and operative management of patients with persisting abdominal complaints after an episode of diverticulitis and/or frequently recurring diverticulitis are applied. However, direct comparison by a randomised controlled trial is necessary to determine which is superior in relieving symptoms, optimising health related quality of life, minimising costs and preventing diverticulitis recurrences against acceptable morbidity and mortality associated with surgery or the occurrence of a complicated recurrence after conservative management. We, therefore, constructed a randomised clinical trial comparing these two treatment strategies. Methods/design: The DIRECT trial is a multicenter randomised clinical trial. Patients (18-75 years) presenting themselves with persisting abdominal complaints after an episode of diverticulitis and/or three or more recurrences within 2 years will be included and randomised. Patients randomised for conservative treatment are treated according to the current daily practice (antibiotics, analgetics and/or expectant management). Patients randomised for elective resection will undergo an elective resection of the affected colon segment. Preferably, a laparoscopic approach is used. The primary outcome is health related quality of life measured by the Gastro-intestinal Quality of Life Index, Short-Form 36, EQ-5D and a visual analogue scale for pain quantification. Secondary endpoints are morbidity, mortality and total costs. The total follow-up

Published
2010
Full Text
View/download PDF

24. Xeno Assistance of the Faling Liver

Author

Stockmann, H.B.A.C. and Stockmann, H.B.A.C.

Abstract

The liver is a highly complex organ in which many different metabolic processes take place. These include the metabolism of dietary carbohydrate, protein and fats, the storage of iron, the formation of hormones and blood coagulation factors and the removal of toxins from the bloodstream. Liver transplants are required when liver function has dropped to below 20% of normal. This can be a result of chronic liver failure, where liver function declines progressively, usually over a period of years, or acute liver failure. The main chronic diseases in adults are cirrhosis, alcohol-induced and non-alcoholic, and hepatitis. In children, the main cause is biliary atresia and other inherited anatomic and metabolic disorders. Acute liver failure is nonnally caused by viral hepatitis or toxic drugs. Acute liver failure is less common than chronic liver failure, but results in brain damage through inflammation and fluid accumulation in the brain, and in 75% of cases the patient dies within a few days of onset. In the few cases where the patient does survive, the liver appears to have an amazing ability to regenerate. Thus far, patients with liver disease are handicapped by the lack

Published
2001

25. Extracorporeal perfusion for the treatment of acute liver failure

Author

Stockmann, H.B.A.C., Hiemstra, C.A., Marquet, R.L. (Richard), IJzermans, J.N.M. (Jan), Stockmann, H.B.A.C., Hiemstra, C.A., Marquet, R.L. (Richard), and IJzermans, J.N.M. (Jan)

Abstract

OBJECTIVE AND SUMMARY BACKGROUND DATA: Because of the shortage of available donor organs, death rates from liver failure remain high. Therefore, several temporary liver-assisting therapies have been developed. This article reviews various approaches to temporary liver support as well as immunologic and metabolic developments toward a solution for this problem. METHODS: A literature review was performed using Medline and additional library searches to obtain further references. Only articles with a well-defined aim of study and methodology and a clear description of the outcome of the experiments were included. CONCLUSIONS: Renewed interest has developed in old and new methods for an extracorporeal approach to the treatment of acute liver failure. Although temporary clinical improvement has been established, further research is needed to achieve a successful long-term clinical outcome. New developments in the field of genetic modification and tissue engineering await clinical application in the near future.

Published
2000

26. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

Author

de Cuba, E.M.V., Snaebjornsson, P., Heideman, D.A.M., van Grieken, N.C.T., Bosch, L.J.W., Fijneman, R.J.A., Belt, E., Bril, H., Stockmann, H.B.A.C., Hooijberg, E., Punt, C.J.A., Koopman, M., Nagtegaal, I.D., Coupé, V.H.M., Carvalho, B., and Meijer, G.A.

Abstract

Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS) CRC. The BRAF V600E mutation has been associated with worse survival in MSS CRC. This mutation occurs in 40% of MSI CRC and it is unclear whether it confers worse survival in this setting. The prognostic value of KRAS mutations in both MSS and MSI CRC remains unclear. We examined the effect of BRAF and KRAS mutations on survival in stage II and III MSI colon cancer patients. BRAF exon 15 and KRAS exon 2-3 mutation status was assessed in 143 stage II (n = 85) and III (n = 58) MSI colon cancers by high resolution melting analysis and sequencing. The relation between mutation status and cancer-specific (CSS) and overall survival (OS) was analyzed using Kaplan-Meier and Cox regression analysis. BRAF V600E mutations were observed in 51% (n = 73) and KRAS mutations in 16% of cases (n = 23). Patients with double wild-type cancers (dWT; i.e., BRAF and KRAS wild-type) had a highly favourable survival with 5-year CSS of 93% (95% CI 84-100%), while patients with cancers harbouring mutations in either BRAF or KRAS, had 5-year CSS of 76% (95% CI 67-85%). In the subgroup of stage II patients with dWT cancers no cancer-specific deaths were observed. On multivariate analysis, mutation in either BRAF or KRAS vs. dWT remained significantly prognostic. Mutations in BRAF as well as KRAS should be analyzed when considering these genes as prognostic markers in MSI colon cancers. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

28. Suspected left sided diverticulitis.

Author

De Korte, N., De Monyé, W., and Stockmann, H.B.A.C.

Subjects
MAGNETIC resonance imaging evaluation, ULTRASONIC imaging -- Evaluation, TOMOGRAPHY, DIVERTICULITIS, DIAGNOSIS
Abstract

The article presents a case study of a 55 year old man admitted to the emergency department with a two day history of progressive pain in the left lower quadrant. He was suspected of having a left sided diverticulitis. Ultrasonography, computed tomography and magnetic resonance imaging are discussed. It states that results of laboratory tests were normal, he was free from pain, and there were no problems with defecation.

Published
2013
Full Text
View/download PDF

29. Improving patient outcomes in colorectal cancer surgery

Author

Abis, G.S.A., Bonjer, H.J., van Egmond, M., Oosterling, S.J., Stockmann, H.B.A.C., Bonjer, Hendrik, van Egmond, Marjolein, and Surgery

Subjects
colorectal cancer outcomes SDD laparoscopic open surgery
Published
2020

30. Diverticulitis Insights in Aetiology and Treatment

Author

de Korte, N., Cuesta, M.A., Boermeester, M.A., Stockmann, H.B.A.C., Cuesta Valentin, Miguel, Surgery, and CCA - Innovative therapy

Abstract

promotiedatum: 4-9-2015 � prom-id: 11418

Published
2015

31. Treatment, follow-up and microbiota in acute diverticulitis

Author

Daniels, L., Boermeester, Marie A., Stockmann, H. B. A. C., Dijkgraaf, Marcel G. W., Other departments, Boermeester, M.A., Stockmann, H.B.A.C., Dijkgraaf, M.G.W., and Faculteit der Geneeskunde

Abstract

Er bestaat veel controverse rondom diverticulitis. Er is tegenstrijdigheid omtrent de beste behandeling van de verschillende stadia. Voor acute ongecompliceerde diverticulitis is het onzeker of antibiotica nodig zijn. De waarde van routine follow-up colonoscopie wordt betwijfeld. Er bestaat onduidelijkheid over de aanpak van recidiverende diverticulitis. Ten slotte is de pathogenese niet geheel bekend. Aan de basis van dit proefschrift staat de DIABOLO trial, een gerandomiseerde multicentrische klinische trial die het effect van antibiotica op het ziektebeloop van acute ongecompliceerde diverticulitis onderzoekt. Tevens werden twee vergelijkende cohort studies en (systematische) reviews uitgevoerd en een hypothese ontwikkeld. De DIABOLO trial toont aan dat antibiotica veilig weggelaten gelaten kunnen worden bij de behandeling van primaire acute ongecompliceerde diverticulitis. Routine follow-up colonoscopie na CT-bewezen ongecompliceerde diverticulitis kan achterwege gelaten worden. Er is weinig bewijs voor medicamenteuze therapieën ter preventie van recidiverende diverticulitis. Diverticulitis patiënten hebben een hogere diversiteit van fecale microbiota dan controles. Middels microbioom analyse kan de diagnose diverticulitis met relatief goede accuratesse gesteld worden. Een veranderde microbiota samenstelling is een plausibele factor in de pathogenese, die waarschijnlijk multifactorieel is en het resultaat van complexe interacties. Bleven internationale richtlijnen eerder ongewijzigd, omdat gesteld werd dat meer onderzoek nodig is alvorens een antibiotica-vrije behandelstrategie in te voeren, nu is er voldoende bewijs voor de implementatie van een observationele behandelstrategie. Hetzelfde geldt voor het achterwege laten van routine follow-up colonoscopie na een CT-bewezen ongecompliceerde episode. Ten aanzien van de darm microbiota zijn verdere studies noodzakelijk. Dit zou kunnen leiden tot diagnostische, preventieve en therapeutische toepassingen.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results